Effects of novel androgen receptor signaling inhibitors on PSMA PET signal intensity in patients with castrate-resistant prostate cancer: a prospective exploratory serial imaging study.
Androgen receptor
Hormonal treatment
PSMA PET
PSMA flare
Prostate cancer
Journal
EJNMMI research
ISSN: 2191-219X
Titre abrégé: EJNMMI Res
Pays: Germany
ID NLM: 101560946
Informations de publication
Date de publication:
30 Oct 2023
30 Oct 2023
Historique:
received:
15
08
2023
accepted:
22
10
2023
medline:
30
10
2023
pubmed:
30
10
2023
entrez:
30
10
2023
Statut:
epublish
Résumé
PSMA expression is influenced by hormonal status. We evaluated changes in PSA and whole-body 68Ga-PSMA-11 PET/CT (WB-PSMA PET) after initiation of androgen receptor signaling inhibitors (ARSi). Prospectively enrolled patients with metastatic castration-resistant prostate cancer (mCRPC) initiating ARSi underwent serial PSA measurements and WB-PSMA PET at baseline, 1-week, and 3-months post-ARSi. We correlated WB-PSMA PET metrics and PSA kinetics after ARSi to 1-year clinical outcome. Due to low enrollment rate, the study was closed before reaching the recruitment goal of 30 patients. Nine patients were enrolled. At 1-year, unfavorable outcome was documented in 6/9 (66%) patients. Nine/9 patients completed PSMA PET at 1-week, 5/9 at 3-months. Changes in PSA, PSMA-VOL, SUVmean and SUVmax were - 12%, + 5%, + 3%, and + 10% at 1-week, - 42%, - 16%, - 15% and - 17% at 3-months, respectively. Our prospective trial involving 9 mCRPC patients initiating ARSi did not show significant modulation of PSMA expression measured on WB-PSMA PET at 1-week. This study was registered on clinicaltrials.gov (NCT04279561).
Sections du résumé
BACKGROUND
BACKGROUND
PSMA expression is influenced by hormonal status. We evaluated changes in PSA and whole-body 68Ga-PSMA-11 PET/CT (WB-PSMA PET) after initiation of androgen receptor signaling inhibitors (ARSi).
METHODS
METHODS
Prospectively enrolled patients with metastatic castration-resistant prostate cancer (mCRPC) initiating ARSi underwent serial PSA measurements and WB-PSMA PET at baseline, 1-week, and 3-months post-ARSi. We correlated WB-PSMA PET metrics and PSA kinetics after ARSi to 1-year clinical outcome.
RESULTS
RESULTS
Due to low enrollment rate, the study was closed before reaching the recruitment goal of 30 patients. Nine patients were enrolled. At 1-year, unfavorable outcome was documented in 6/9 (66%) patients. Nine/9 patients completed PSMA PET at 1-week, 5/9 at 3-months. Changes in PSA, PSMA-VOL, SUVmean and SUVmax were - 12%, + 5%, + 3%, and + 10% at 1-week, - 42%, - 16%, - 15% and - 17% at 3-months, respectively.
CONCLUSIONS
CONCLUSIONS
Our prospective trial involving 9 mCRPC patients initiating ARSi did not show significant modulation of PSMA expression measured on WB-PSMA PET at 1-week. This study was registered on clinicaltrials.gov (NCT04279561).
Identifiants
pubmed: 37902861
doi: 10.1186/s13550-023-01048-4
pii: 10.1186/s13550-023-01048-4
pmc: PMC10616012
doi:
Banques de données
ClinicalTrials.gov
['NCT04279561']
Types de publication
Journal Article
Langues
eng
Pagination
95Informations de copyright
© 2023. The Author(s).
Références
Proc Natl Acad Sci U S A. 2011 Jun 7;108(23):9578-82
pubmed: 21606347
Eur J Nucl Med Mol Imaging. 2023 Jan;50(2):613-621
pubmed: 36161511
Cancer Res. 1994 Apr 1;54(7):1807-11
pubmed: 7511053
BJU Int. 2021 Aug;128(2):127-130
pubmed: 34318983
J Nucl Med. 2019 Sep;60(9):1277-1283
pubmed: 30850484
J Natl Compr Canc Netw. 2019 May 1;17(5):479-505
pubmed: 31085757
Clin Nucl Med. 2018 Nov;43(11):e404-e406
pubmed: 30222680
Nucl Med Mol Imaging. 2017 Sep;51(3):202-211
pubmed: 28878845
J Nucl Med. 2019 Jul;60(7):950-954
pubmed: 30552200
EJNMMI Res. 2018 Oct 29;8(1):96
pubmed: 30374743
Eur Urol Oncol. 2018 May;1(1):78-82
pubmed: 31100231